Share “Tranzyme board to explore sale, other...”

Tranzyme board to explore sale, other alternatives

Published on NewsOK Modified: February 8, 2013 at 6:39 am •  Published: February 8, 2013
Advertisement

DURHAM, N.C. (AP) — Tranzyme Inc.'s board of directors will explore a possible sale, merger or business combination for the drug developer, which recently ended research into its most advanced experimental treatment.

The Durham, N.C., company said Friday it has not decided on any specific alternative, and it has no time frame for completing its review.

Tranzyme has no drugs on the market. It said in December it would end a mid-stage study of a treatment for diabetic gastroparesis because it failed to do better than a placebo. Gastroparesis is a condition in which the stomach takes too long to clear out food.

The company also is developing possible treatments for diarrhea caused by chemotherapy and for metabolic diseases.

Tranzyme shares closed at 56 cents per share on Thursday.


AROUND THE WEB

  1. 1
    ONEOK Partners to invest up to $100 million to expand capacity in Permian Basin
  2. 2
    Report: Thunder signs Josh Huestis to 4-year deal
  3. 3
    Thunder TV analyst Nancy Lieberman expected to become Kings assistant coach
  4. 4
    Dodgers send Olivera to Braves in three-way trade
  5. 5
    MTV's 'Real World' sets casting call in Oklahoma City
+ show more

FEATURED JOBS



× Trending business Article